Personal Information

     Professor

     Director of China-Sweden International Joint Research Center for Brain Diseases                                                                         

     School of Life Sciences,

     Shaanxi Normal University,

     Xi’an 710062, China

      E-mail: zlsnnu@gmail.com

Education

     2010 – 2015 Ph. D. in Medical Science, Uppsala University, Sweden

     2008 – 2010 M. S. in Applied Biotechnology, Uppsala University, Sweden

     2004 – 2008 B. S. in Biology, Shaanxi Normal University, China

Working Experience

      2017---present Professor of Life Sciences, School of Life Sciences, Shaanxi Normal University,

      2015---2017 Postdoc Researcher (Anna Dimberg group) Department of Immunology, Genetics and Pathology, Uppsala University, Sweden

Research Projects

1. Development of a therapeutic vaccine against pleiotrophin as a novel glioblastoma treatment; the National Natural Science Foundation of China (NSFC)/the Swedish Foundation for International Cooperation in Research and Higher Education (STINT) Mobility Program; 81911530166; 2019-2021.

2. Development of a therapeutic vaccine against pleiotrophin as a novel glioblastoma treatment; National Natural Science Foundation of China; 81702489; 2018—2020.

3. Overseas High-level Talents Program of Shaanxi; 2019-2024.

4. Development of a therapeutic vaccine for glioblastoma; the Key R&D Program of Shaanxi province; 2021KW-46; 2021-2022.

Research Interests

     1. Reveal molecular regulation of blood-brain barrier and blood-tumor barrier by using of the-state-of-the-art technology including single cell sequencing and other omics technologies

     2. Uncover novel vascular targets to improve drug delivery for brain diseases including glioblastoma.

Publications

    1. Zhang L, Kundu S, Feenstra T, Li X, Jin C, Laaniste L, El Hassan TE, Ohlin KE, Yu D, Olofsson T, Olsson AK, Ponten F, Magnusson PU, Nilsson KF, Essand M, Smits A, Dieterich LC, Dimberg A (2015) Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas. Sci Signal 8: ra125；IF：9.517

    2. Zhang L, He L, Lugano R, Roodakker K, Bergqvist M, Smits A, Dimberg A (2018) IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas. Neuro Oncol 20: 1505-1516 ；IF：13.029

    3. Xie Y, He L, Lugano R, Zhang Y, Cao H, He Q, Chao M, Liu B, Cao Q, Wang J, Jiao Y, Hu Y, Han L, Zhang Y, Huang H, Uhrbom L, Betsholtz C, Wang L, Dimberg A, Zhang L* (2021) Key molecular alterations in endothelial cells in human glioblastoma uncovered through single-cell RNA sequencing. JCI Insight ；IF：9.484

    4. Zhang Y, Xie Y, He L, Tang J, He Q, Cao Q, Cui L, Guo W, Hua K, Dimberg A, Wang L, Zhang L* (2020) 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas. Cell Oncol (Dordr) ；IF：7.051

    5. Yang F, Xie Y, Tang J, Liu B, Luo Y, He Q, Zhang L, Xin L, Wang J, Wang S, Zhang S, Cao Q, Wang L, He L, Zhang L* (2021) Uncovering a Distinct Gene Signature in Endothelial Cells Associated With Contrast Enhancement in Glioblastoma. Front Oncol 11: 683367 ；IF：5.738